Participation of hypothalamic CB 1 receptors in reproductive axis disruption during immune challenge

Immune challenge inhibits reproductive function and endocannabinoids ( eCB ) modulate sexual hormones. However, no studies have been performed to assess whether the eCB system mediates the inhibition of hormones that control reproduction as a result of immune system activation during systemic infections. For that reason, we evaluated the participation of the hypothalamic cannabinoid receptor CB 1 on the hypothalamic‐pituitary‐gonadal ( HPG ) axis activity in rats submitted to immune challenge. Male adult rats were treated i.c.v. administration with a CB 1 antagonist/inverse agonist ( AM 251) (500 ng/5 μL), followed by an i.p. injection of lipopolysaccharide ( LPS ) (5 mg/kg) 15 minutes later. Plasmatic, hypothalamic and adenohypophyseal pro‐inflammatory cytokines, hormones and neuropeptides were assessed 90 or 180 minutes post‐ LPS . The plasma concentration of tumour necrosis factor α and adenohypophyseal mRNA expression of Tnf α and Il1 β increased 90 and 180 minutes post i.p. administration of LPS . However, cytokine mRNA expression in the hypothalamus increased only 180 minutes post‐ LPS , suggesting an inflammatory delay in this organ. CB 1 receptor blockade with AM 251 increased LPS inflammatory effects, particularly in the hypothalamus. LPS also inhibited the HPG axis by decreasing gonadotrophin‐releasing hormone hypothalamic content and plasma levels of luteinising hormone and testosterone. These disruptor effects were accompanied by decreased hypothalamic Kiss1 mRNA expression and prostaglandin E2 content, as well as by increased gonadotrophin‐inhibitory hormone ( Rfrp3 ) mRNA expression. All these disruptive effects were prevented by the presence of AM 251. In summary, our results suggest that, in male rats, eCB mediate immune challenge‐inhibitory effects on reproductive axis at least partially via hypothalamic CB 1 activation. In addition, this receptor also participates in homeostasis recovery by modulating the inflammatory process taking place after LPS administration.